
Business
Neurocrine to Acquire Soleno Therapeutics for $2.9B, Expanding Rare Disease Portfolio
Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a $2.9 billion all-cash transaction, reinforcing its strategic expansion into endocrinology and rare disease treatments. Under


